Authorized generics for hypertension treatment announced
Sandoz, the generic pharmaceuticals division of Novartis, has introduced an authorized generic version of Diovan (valsartan) tablets for the treatment of hypertension. The generic version of Diovan will be available in 40 mg, 80 mg, 160 mg, and 320 mg strength tablets, the same strength as the branded version.
Sandoz, the generic pharmaceuticals division of Novartis, has introduced an authorized generic version of Diovan (valsartan) tablets for the treatment of hypertension. The generic version of Diovan will be available in 40 mg, 80 mg, 160 mg, and 320 mg strength tablets, the same strength as the branded version.
This launch follows the Sandoz introduction of an authorized generic version of Diovan HCT (valsartan and hydrochlorothiazide) two years ago. Both Diovan and Diovan HCT are marketed in the United States by Novartis Pharmaceuticals Corp. U.S. net sales for Diovan and Diovan HCT in 2013 were $1.7 billion.
Greenstone LLC, a U.S.-based subsidiary of Pfizer Inc., is offering its authorized generic of Cardura (doxazosin mesylate) tablets for the treatment of hypertension and for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with benign prostatic hyperplasia.
The generic version of Cardura will be offered in dosage strengths of 1 mg, 2 mg, 4 mg, and 8 mg.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
